Health & Biotech
Check out the latest news, insights and unique analysis brought to you by Stockhead's team of business journalists and industry experts on Zelira Therapeutics.
RELATED STOCKHEAD STORIES
Health & Biotech
Clinical results for ancient therapy help ASX cannabis stocks weed out competition
Health & Biotech
How Bod Science pulled ahead in the race for Australia’s first over-the-counter CBD
Health & Biotech
These were the best ASX biotechs as Health Care sprang back to life in FY23
Health & Biotech
ASX-listed Zelira is going head-to-head with Big Pharma. We spoke to its CEO about its place in a US$62 billion market
Health & Biotech
Weed Week: Storm before the calm as cannabis market set to boom after SAFE Banking Act passed
Health & Biotech
Check Up: Here’s the handful of ASX small cap health stocks that actually pay dividends
News
ASX Small Caps and Weekly IPO Wrap: Investors find Solis during a sweaty, confusing week
Health & Biotech
Weed Week: A ‘shroom boom’ could see psychedelics follow cannabis’ explosive footsteps
Health & Biotech
ASX Biotech Winners in May: We’re finally seeing signs of life on the back of another clinical breakthrough
News
ASX May Winners: Mid caps beat large caps; small caps lag. May was tough.
News
Rise and Shine: Everything you need to know before the ASX opens
News
CLOSING BELL: A massive win for Zelira’s new pain drug has polished an absolute turd of a day
News
In Case You Missed It: Cannabis play leads by miles
News
ASX Small Caps Lunch Wrap: Who wants to play a game of Good News and Bad News this morning?
Health & Biotech
ASX Health Stocks: Zelira skyrockets 200pc after saying that its drug works better than Pfizer’s Lyrica
News
Banking on pot: Minus one global investment house, Switzerland moves to legalise cannabis
News